APOE: a potential marker of disease progression in ALS.
Although documented in AD, the role of APOE remains unclear in ALS. APOE phenotype and plasma levels were measured in 403 patients with ALS and were correlated with clinical parameters and survival time. No correlations were observed between the APOE phenotype and these variables. In contrast, APOE plasma levels were correlated with both rate of deterioration and survival time and appeared to be an important risk factor for decreased survival time with a relative risk of 0.647 (95% CI: 0.465 to 0.901; p = 0.01).
Lacomblez
L
L
Fédération de Neurologie Mazarin, Service de Pharmacologie, AP-HP, Hôpital de la Salpêtrière, Paris, France.
Doppler
V
V
Beucler
I
I
Costes
G
G
Salachas
F
F
Raisonnier
A
A
Le Forestier
N
N
Pradat
P-F
PF
Bruckert
E
E
Meininger
V
V
D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000097:blood / Q000235:genetics*; D001057:Apolipoproteins E / Q000097:blood / Q000235:genetics*; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D016001:Confidence Intervals; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010641:Phenotype; D016016:Proportional Hazards Models; D011446:Prospective Studies
D001057:Apolipoproteins E; D015415:Biomarkers